by BENJAMIN WERNER CHRISTENSEN, translated by daniel pedersen
While Novo Nordisk has taken the center stage of the obesity market in the US, the Danish pharmaceutical firm’s archrival there, Eli Lilly, is plotting ways to commercially challenge Wegovy with its own candidate, tirzepatide.
”Based on our current data, we look forward to going through the data with the FDA [US Food and Drug Administration, -ed.] to discuss the possibility of receiving an accelerated pathway in this indication,” said Dan Skovronsky, chief scientific and medical officer of Eli Lilly, during a teleconference for analysts and investors.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers.
Start a free company trial todayMore from MedWatch
GN purchase story is very speculative, says analyst
Competition rules could block a purchase of GN Store Nord and subsequent divestment of GN Hearing, says a Sydbank analyst on the speculative story that this might be underway.
Novo Nordisk invests additional millions of dollars in new manufacturing facilities
Novo Nordisk’s DKK 17bn (USD 2.4bn) investment into upgrading and building new facilities in Kalundborg last year has now been followed by a DKK 1bn (USD 143.8m) investment in the same location.
CHMP to remove 100 generic medicines from market
Due to fraudulent clinical trials from a contract research organization, the EMA’s expert committee, the CHMP, is now suspending marketing approval authorizations for around 100 generic drugs on the market.
Germany orders 40,000 monkeypox vaccines from Bavarian Nordic
The German Minister for Health has revealed that the German state has ordered vaccines from Bavarian Nordic, as the country reports 5 cases of monkeypox.
New head of research at Astellas Gene Therapies: "Choosing the right indications is extra important"
Morten Søgaard is leaving Pfizer to join Astellas, where he will be in charge of 100 employees. Going from one of the world largest pharmaceutical firms to a considerably smaller one will be a challenge, he says.
KLIFO is looking for a Clinical Supply Manager for our Glostrup office 
Clinical Trial Manager for development of in vitro diagnostics 
Senior Chemical Safety Advisor 
Nordic Medical Affairs Manager 
Analytical Senior Scientist 
Key Account Manager, Europe and Asia 
Innovation Project Manager, Display Unit 
Consultant Manager 
Senior QA Specialist 
Director for innovative pre-clinical testing unit 
Laboratory technician for process development and clinical manufacturing 
Senior Project Manager (GMP - Life Science) 
Senior Manager, Clinical Trial Budget 
Production Director 
Clinical Trial Manager 
Project Manager & Scrum Master